Like my fellow sparring partner, Ryan Fuhrmann, I too consider myself to be a contrarian investor. Full Article at Motley Fool

There's little doubt that companies in the Dow Jones Industrial average appear to defy logic, despite market capitalizations in the hundreds of billions of dollars. Johnson & Johnson (NYSE: JNJ) is such a firm. Full Article at Motley Fool

With a market cap of more than $190 billion, health-care giant Johnson & Johnson (NYSE: JNJ) has become the victim of its own success. It continues to grow sales and earnings and produce positive results in its R&D pipeline. Full Article at Motley Fool